SI1797109T1 - Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe - Google Patents

Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe

Info

Publication number
SI1797109T1
SI1797109T1 SI200532068A SI200532068A SI1797109T1 SI 1797109 T1 SI1797109 T1 SI 1797109T1 SI 200532068 A SI200532068 A SI 200532068A SI 200532068 A SI200532068 A SI 200532068A SI 1797109 T1 SI1797109 T1 SI 1797109T1
Authority
SI
Slovenia
Prior art keywords
polypeptides
mixtures
processes
compositions containing
preparing same
Prior art date
Application number
SI200532068A
Other languages
English (en)
Inventor
Irit Pinchasi
Ben-Zion Dolitzky
Anton Frenkel
Michal Schwartz
Ruth Arnon
Rina Aharoni
Original Assignee
Yeda Research And Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co., Ltd. filed Critical Yeda Research And Development Co., Ltd.
Publication of SI1797109T1 publication Critical patent/SI1797109T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200532068A 2004-09-09 2005-09-09 Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe SI1797109T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60884404P 2004-09-09 2004-09-09
PCT/US2005/032553 WO2006029411A2 (en) 2004-09-09 2005-09-09 Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
EP05795337.4A EP1797109B1 (en) 2004-09-09 2005-09-09 Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof

Publications (1)

Publication Number Publication Date
SI1797109T1 true SI1797109T1 (sl) 2016-07-29

Family

ID=36037053

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200532068A SI1797109T1 (sl) 2004-09-09 2005-09-09 Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe

Country Status (11)

Country Link
US (2) US7560100B2 (sl)
EP (1) EP1797109B1 (sl)
CY (1) CY1117704T1 (sl)
DK (1) DK1797109T3 (sl)
ES (1) ES2572811T3 (sl)
HR (1) HRP20160455T1 (sl)
HU (1) HUE028833T2 (sl)
IL (1) IL181802A (sl)
PL (1) PL1797109T3 (sl)
SI (1) SI1797109T1 (sl)
WO (1) WO2006029411A2 (sl)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ATE475883T1 (de) * 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
SI1592384T1 (sl) * 2003-01-21 2013-03-29 Yeda Research And Development Co., Ltd. The Weizmann Institute Of Science Kopolimer 1 za zdravljenje vnetnih ÄŤrevesnih bolezni
KR20060097020A (ko) * 2003-10-31 2006-09-13 테바 파마슈티컬 인더스트리즈 리미티드 약물 전달용 나노입자
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
KR101347562B1 (ko) * 2004-06-25 2014-01-03 더 브리검 앤드 우먼즈 하스피털, 인크. 신경계 장애의 치료를 위한 조성물 및 방법
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
BRPI0515033B1 (pt) * 2004-09-09 2021-05-25 Teva Pharmaceutical Industries, Ltd Processo para a obtenção de uma mistura de polipeptídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica e para a produção de acetato de glatirâmero
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
DK1848415T3 (da) * 2005-02-17 2013-07-08 Teva Pharma Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
EP1973475B1 (en) * 2006-01-17 2010-07-14 Baxter International Inc. Device, system and method for mixing
CA2650653C (en) 2006-04-28 2016-03-29 Momenta Pharmaceuticals, Inc. Methods of evaluating glatiramer acetate
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2173766A1 (en) * 2007-07-31 2010-04-14 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
WO2009021007A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
EP2044951A1 (en) * 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US20090149541A1 (en) * 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
CA2707010A1 (en) * 2007-12-14 2009-06-25 Kazuhisa Sugimoto .alpha.-lipoic acid nanoparticles and methods for preparing thereof
RU2010146489A (ru) 2008-04-16 2012-05-27 Момента Фармасьютикалз, Инк. (Us) Анализ композиций сополимера аминокислот
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
SI3085381T1 (sl) * 2008-05-21 2018-06-29 Ferring B.V. Orodisperzibilen dezmopresin za povečanje začetnega obdobja spanja, ki ga ne moti nokturija
EP2307448B1 (en) * 2008-08-07 2015-04-22 Sigma-Aldrich Co. LLC Preparation of low molecular weight polylysine and polyornithine in high yield
JP2011530523A (ja) * 2008-08-07 2011-12-22 サイノファーム タイワン リミテッド 酢酸グラチラマーの合成
US9617313B2 (en) * 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
EP3192500B1 (en) * 2009-05-19 2020-12-02 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
ATE549013T1 (de) * 2009-07-15 2012-03-15 Teva Pharma Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
RS54707B1 (en) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. TREATMENT OF CROWN LAKVINIMOD DISEASE
RS55071B1 (sr) * 2009-08-10 2016-12-30 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
PL2949335T3 (pl) 2009-08-20 2017-07-31 Yeda Research & Development Company, Ltd. Terapia octanem glatirameru podawanym z niewielką częstotliwością
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8641661B2 (en) 2010-01-05 2014-02-04 Baxter International Inc. Mixing system, kit and mixer adapter
CA2726566A1 (en) * 2010-01-11 2011-07-11 Baxter International Inc. Pipette system, pipette tip assembly and kit
CA2791709A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
PE20181523A1 (es) * 2010-03-03 2018-09-24 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP2013535474A (ja) * 2010-07-29 2013-09-12 ドクター レディズ ラボラトリーズ リミテッド グラチラマー酢酸塩の分子量マーカー
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
EP2627669B1 (en) 2010-10-11 2016-08-17 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CN103442693A (zh) 2010-11-15 2013-12-11 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
WO2012067974A1 (en) * 2010-11-17 2012-05-24 Sigma-Aldrich Co. Llc. A greener method for the production of copolymer 1
AU2011338647A1 (en) * 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
WO2012112933A1 (en) * 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
KR20140027174A (ko) 2011-03-24 2014-03-06 옵코 파마슈티칼스, 엘엘씨 비드 또는 입자 기초 라이브러리들, 진단적 키트들을 및 치료제들을 사용한 복합 생물학적 유체에서 바이오마커 발견
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US20140288269A1 (en) * 2011-11-03 2014-09-25 Biocon Limited Process for the preparation of random polypeptides and employing circular dichroism as a guidance tool for the manufacture of glatiramer acetate
JP2015506918A (ja) * 2011-12-12 2015-03-05 バイオコン・リミテッド 前臨床および臨床マトリクス中のペプチドポリマーの薬物動態評価のための特異的免疫アッセイ関連試薬の開発
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
BR112014030265A2 (pt) 2012-06-05 2017-06-27 Neuroderm Ltd composição farmacêutica líquida ou semissólida e método para tratar uma doença ou distúrbio neurológico ou de movimento.
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
US20150246061A1 (en) * 2012-10-19 2015-09-03 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
AU2014244550B2 (en) 2013-03-14 2018-11-01 Mylan Inc. Glatiramer acetate response biomarker mRNA potency assay
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
TWI717314B (zh) * 2013-10-24 2021-02-01 美商麥蘭股份有限公司 供評估格拉默醋酸鹽製備物之免疫同一性用的人類ｔ細胞株分析方法
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
FI3777833T3 (fi) 2014-03-13 2024-01-03 Neuroderm Ltd Dopa-dekarboksylaasin estäjän koostumuksia
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2015195605A1 (en) * 2014-06-17 2015-12-23 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate by oral patches
CN105218646B (zh) * 2014-06-24 2018-09-21 深圳翰宇药业股份有限公司 一种用于检测醋酸格拉替雷样本的uplc方法
CN104844697B (zh) * 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US20180164275A1 (en) * 2015-04-30 2018-06-14 Teva Pharmaceutical Industries Ltd. Method of determining the molecular weight distribution of glatiramer acetate using multi-angle laser light scattering (malls)
CA3016917A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
CN107550853B (zh) * 2016-06-30 2020-06-12 深圳翰宇药业股份有限公司 一种醋酸格拉替雷注射液的制备方法
BR112019004929A2 (pt) 2016-09-13 2019-06-04 Allergan Inc composições de toxina clostridial não proteíca
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
JP2020512314A (ja) 2017-03-27 2020-04-23 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． サシツズマブゴビテカンとＲＡＤ５１阻害剤を用いたＴｒｏｐ−２発現トリプルネガティブ乳癌の治療
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US20190202984A1 (en) * 2018-01-03 2019-07-04 Kinbio Ltd. Process of preparing glatiramer acetate
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11497765B1 (en) 2022-02-27 2022-11-15 King Abdulaziz University Thioctamer expedites wound healing

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) * 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
AR247097A1 (es) 1985-06-18 1994-11-30 Univ Emory Procedimiento para preparar composiciones farmaceuticas que incluyen copolimeros biologicamente activos como agente activo.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL140592A0 (en) * 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DK2239269T3 (da) 1998-09-25 2013-04-29 Yeda Res & Dev Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP1128839A4 (en) * 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
AU780188B2 (en) * 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
AU2001238469C1 (en) 2000-02-18 2006-08-24 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
IL153236A0 (en) 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ATE475883T1 (de) 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
US7309334B2 (en) * 2002-07-23 2007-12-18 Von Hoffmann Gerard Intracranial aspiration catheter
AU2003283152A1 (en) 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
SI1592384T1 (sl) * 2003-01-21 2013-03-29 Yeda Research And Development Co., Ltd. The Weizmann Institute Of Science Kopolimer 1 za zdravljenje vnetnih ÄŤrevesnih bolezni
WO2004091573A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
EP1638589B1 (en) * 2003-05-14 2014-03-26 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
KR20060097020A (ko) 2003-10-31 2006-09-13 테바 파마슈티컬 인더스트리즈 리미티드 약물 전달용 나노입자
WO2005048435A1 (de) * 2003-11-13 2005-05-26 Sew-Eurodrive Gmbh & Co. Kg Kompaktantrieb
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
BRPI0515033B1 (pt) * 2004-09-09 2021-05-25 Teva Pharmaceutical Industries, Ltd Processo para a obtenção de uma mistura de polipeptídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica e para a produção de acetato de glatirâmero
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
AU2005302500B2 (en) 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
WO2007030573A2 (en) * 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20080021192A1 (en) 2006-07-05 2008-01-24 Momenta Pharmaceuticals, Inc. Process for the preparation of copolymer-1

Also Published As

Publication number Publication date
DK1797109T3 (en) 2016-04-11
IL181802A (en) 2016-10-31
HRP20160455T1 (hr) 2016-07-15
EP1797109A2 (en) 2007-06-20
EP1797109A4 (en) 2009-06-17
HUE028833T2 (en) 2017-01-30
WO2006029411A3 (en) 2006-08-03
PL1797109T3 (pl) 2016-11-30
US7560100B2 (en) 2009-07-14
IL181802A0 (en) 2007-07-04
US20060122113A1 (en) 2006-06-08
EP1797109B1 (en) 2016-02-24
US20070054857A1 (en) 2007-03-08
ES2572811T3 (es) 2016-06-02
WO2006029411A2 (en) 2006-03-16
CY1117704T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
HRP20160455T1 (hr) Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
IL169500A0 (en) Pyrrolopyridazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL195580A (en) L – fkbp polypeptides, preparations containing them, methods of preparation and use
IL181618A0 (en) Pharmaceutical solid-in-oil compositions for external administraton, methods for preparation and uses thereof
IL209386A0 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
IL182947A0 (en) Chimeric polypeptides and pharmaceutical compositions containing the same
IL180397A0 (en) Diamine derivatives, fungicidal compositions containing the same, and processes for the preparation thereof
IL183346A0 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ZA200800781B (en) Powdered lime composition, method of preparing same and use thereof
PL1765967T3 (pl) Mieszany proszek lub mieszany granulat na bazie mgda
ZA200701689B (en) Silane compositions, processes for their preparation and rubber compositions containing same
ZA200702226B (en) Compounds, compositions containing them, preparations thereof and uses thereof II
PL1751249T3 (pl) Kompozycje samorzutnie wydzielające parę wodną, wyroby obejmujące takie kompozycje i sposoby wytwarzania takich kompozycji
IL177143A0 (en) Compositions, methods and uses for a novel family of peptides
IL183928A0 (en) Bcma polypeptides, their preparation and pharmaceutical compositions containing them
IL182126A (en) Preparations containing and used in the history of 5-phenoxyalkoxypsoralen
IL183044A0 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
IL154370A0 (en) Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
ZA200801896B (en) Slow-release composition, method for the preparation thereof, and use of the same
EP1797078A4 (en) BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES, PREPARATION AND USES THEREOF
EP1758577A4 (en) NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF ADMINISTRATION THEREFOR
IL181683A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL181022A0 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same
ZA200704925B (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
IL179670A0 (en) Heterocyclic compounds and processes for the preparation thereof